 |
crohnscanada.myfastforum.org Inform Canadians of the evidence linking Crohn's disease to Mycobacterium Avium Paratuberculosis and Johne's disease in animals
|
BEWARE OF SCAMMERS ASKING FOR ADMIN ACCESS. WE NEVER ASK FOR ACCESS.
| View previous topic :: View next topic |
| Author |
Message |
admin Site Admin
Joined: 06 Jan 2008 Posts: 45
|
Posted: Thu Jan 24, 2008 1:14 am Post subject: Giaconda Signs Agreement to Take Myoconda® to Market in Euro |
|
|
GIACONDA Sydney, Australia 19 September 2007. Giaconda Ltd (ASX: GIA) today announced that it has entered a cooperative development agreement with Prague Clinical Services, s.r.o. of the Czech Republic to further the development of its lead product, Myoconda®, for the treatment of MAP infection in Crohn’s Disease. Under the terms of the agreement Giaconda and Prague Clinical Services will collaborate to complete a Phase III clinical study across Europe as well as regulatory development on Myoconda to enable registration with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.
|
|
| Back to top |
|
 |
|
|
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum
|
|